Background
Objective
Study Design
Results
Conclusion
Key words
Introduction
Materials and Methods
Study design
Subjects
EF aspiration
VA collection
Endometrial receptivity diagnosis
Genomic DNA isolation from EF and VA samples
Polymerase chain reaction and 16S rRNA sequencing
Taxonomic assignment and bioinformatics
Taxonomic classifications
Alpha diversity
Community clustering analysis
Principal component analysis of microbial communities
Statistical analysis
Results
Endometrial and vaginal microbiota differ in some asymptomatic subjects




The endometrial microbiota

Regulation of endometrial microbiota during the acquisition of endometrial receptivity


Functional impact of the endometrial microbiota composition on reproductive outcome in patients undergoing IVF
Sample | Endometrial receptivity (d) | Shannon index | Lactobacillus OTUs, % | Non-Lactobacillus OTUs, % | Unassigned, % | Endometrial microbiota | Pregnancy | Ongoing pregnancy |
---|---|---|---|---|---|---|---|---|
1 | R (P+5) | 3.090 | 90.85 | 5.35 | 3.80 | LD | Yes | Yes |
2 | R (P+5) | 3.079 | 95.10 | 2.13 | 2.77 | LD | Yes | Yes |
3 | R (P+5) | 4.257 | 66.48 | 31.28 | 2.24 | NLD | Yes | Yes (VTOP) |
4 | R (P+5) | 1.510 | 99.57 | 0.12 | 0.32 | LD | Yes | Yes |
5 | R (P+7) | 4.216 | 93.37 | 6.16 | 0.47 | LD | Yes | Yes |
6 | R (CD21) | 2.681 | 91.12 | 7.11 | 1.77 | LD | Yes | Yes |
7 | R (LH+7) | NA | No data | NA | Yes | Yes | ||
8 | R (P+5) | NA | No data | NA | Yes | No | ||
9 | R (P+7) | 1.550 | 3.27 | 94.36 | 2.37 | NLD | Yes | No |
10 | R (P+5) | 0.557 | 0.07 | 98.26 | 1.66 | NLD | Yes | No |
11 | R (P+5) | 1.316 | 0.26 | 85.43 | 14.31 | NLD | Yes | Yes |
12 | R (LH+6) | 1.527 | 99.54 | 0.32 | 0.15 | LD | Yes | Yes |
13 | R (P+5) | 3.288 | 97.35 | 2.40 | 0.25 | LD | Yes | No |
14 | R (P+3.5) | 5.834 | 36.11 | 58.24 | 5.65 | NLD | Yes | No |
15 | R (P+5) | 0.964 | 98.73 | 1.14 | 0.12 | LD | Yes | Yes |
16 | R (CD21) | 1.153 | 99.35 | 0.50 | 0.15 | LD | Yes | No |
17 | R (CD20) | 2.443 | 99.91 | 0.07 | 0.03 | LD | Yes | Yes |
18 | R (P+6) | 2.282 | 99.93 | 0.01 | 0.06 | LD | Yes | Yes |
19 | R (P+5) | 0.550 | 99.77 | 0.22 | 0.01 | LD | Yes | Yes |
20 | R (P+4.5) | NA | No data | NA | Yes | Yes | ||
21 | R (P+5) | 1.168 | 0.29 | 99.34 | 0.36 | NLD | No | NA |
22 | R (P+5) | 2.799 | 7.68 | 90.53 | 1.79 | NLD | No | NA |
23 | R (P+5) | 2.504 | 88.96 | 10.39 | 0.65 | NLD | No | NA |
24 | R (P+5) | 3.499 | 4.26 | 95.66 | 0.07 | NLD | No | NA |
25 | R (P+5) | 2.886 | 87.86 | 7.19 | 4.96 | LD | No | NA |
26 | R (P+5) | 4.954 | 3.43 | 95.31 | 1.26 | NLD | No | NA |
27 | R (P+5) | 1.900 | 92.70 | 5.74 | 1.55 | LD | No | NA |
28 | R (P+5) | 4.699 | 66.82 | 29.83 | 3.35 | NLD | No | NA |
29 | R (P+7) | 0.469 | 1.23 | 98.63 | 0.14 | NLD | No | NA |
30 | R (CD22) | 1.503 | 99.70 | 0.09 | 0.22 | LD | No | NA |
31 | R (P+5) | 4.639 | 73.89 | 23.81 | 2.30 | NLD | No | NA |
32 | R (P+5) | 1.927 | 4.62 | 95.22 | 0.16 | NLD | No | NA |
33 | R (P+5) | 0.805 | 98.00 | 1.96 | 0.05 | LD | No | NA |
34 | R (P+5) | 0.696 | 99.89 | 0.11 | 0 | LD | No | NA |
35 | R (P+5) | 3.202 | 87.70 | 12.20 | 0.11 | NLD | No | NA |
36 | NR (P+5) | 2.297 | 39.64 | 58.98 | 1.38 | NLD | No ET | NA |
37 | NR (P+5) | 5.274 | 16.34 | 82.92 | 0.74 | NLD | No ET | NA |
38 | NR (P+5) | 3.609 | 96.43 | 3.26 | 0.31 | LD | No ET | NA |
39 | NR (P+3) | 4.651 | 22.38 | 63.72 | 13.91 | NLD | No ET | NA |
40 | NR (P+5) | 4.026 | 14.07 | 84.30 | 1.63 | NLD | No ET | NA |
41 | NR (P+4) | 2.013 | 97.94 | 1.77 | 0.29 | LD | No ET | NA |



Characteristics and outcomes | LDM, n = 17 | NLDM, n = 15 | P value |
---|---|---|---|
Age, y | 40.06 ± 3.47 | 39.00 ± 5.09 | .49 |
BMI, kg/m2 | 24.18 ± 5.18 | 22.45 ± 4.02 | .30 |
Previous pregnancies | 1.71 ± 2.44 | 1.53 ± 2.32 | .84 |
Previous miscarriages | 1.53 ± 2.21 | 1.14 ± 1.56 | .58 |
Metaphase II oocytes/cycle | 11.94 ± 4.27 | 10.20 ± 4.81 | .28 |
Fertilization rate/cycle | 157/203 (77.34%) | 118/153 (77.12%) | .62 |
Transferred embryos/cycle | 1.65 ± 0.49 | 1.73 ± 0.59 | .65 |
Time between EF and transfer, mo | 2.82 ± 2.55 | 1.80 ± 1.08 | .16 |
Pregnancy rate/transfer | 12/17 (70.6%) | 5/15 (33.3%) | .03, |
Implantation rate/transfer | 17/28 (60.7%) | 6/26 (23.1%) | .02, |
Ongoing pregnancy/transfer | 10/17 (58.8%) | 2/15 (13.3%) | .02, |
Miscarriage rates | 2/12 (16.7%) | 3/5 (60%) | .07 |
Live birth rate/transfer | 10/17 (58.8%) | 1/15 (6.7%) | .002, |



Patient | EF sample in Table 1 | Sample (d) | ERA test | Embryo transfer | Lactobacillus OTUs, % | Non- Lactobacillus OTUs, % | Unassigned, % | Microbiomic profile | Pregnancy | Ongoing pregnancy |
---|---|---|---|---|---|---|---|---|---|---|
1 | 36 | 1A (P+5) | NR (P+5) | No | 39.64 | 58.98 | 1.38 | NLD | NA | NA |
5 | 1B (P+7) | R (P+7) | P+7 | 93.37 | 6.16 | 0.47 | LD | Yes | Yes | |
2 | 37 | 2A (P+5) | NR (P+5) | No | 16.34 | 82.92 | 0.74 | NLD | NA | NA |
9 | 2B (P+7) | R (P+7) | P+7 | 3.27 | 94.36 | 2.37 | NLD | Yes | No | |
3 | 39 | 3A (P+3) | NR (P+3) | No | 22.38 | 63.72 | 13.91 | NLD | NA | NA |
14 | 3B (P+3.5) | R (P+3.5) | P+3.5 | 36.11 | 58.24 | 5.65 | NLD | Yes | No | |
4 | 40 | 4A (P+5) | NR (P+5) | No | 14.07 | 84.30 | 1.63 | NLD | NA | NA |
29 | 4B (P+7) | R (P+7) | P+7 | 1.23 | 98.63 | 0.14 | NLD | No | NA | |
5 | 38 | 5A (P+5) | NR (P+5) | No | 96.43 | 3.26 | 0.31 | LD | NA | NA |
41 | 5B (P+4) | NR (P+4) | No | 97.94 | 1.77 | 0.29 | LD | NA | NA | |
20 | 5C (P+4.5) | R (P+4.5) | P+4.5 | No amplification | NA | Yes | Yes |
Comment
Principal findings of the study
Is there an endometrial microbiota different that is from the vaginal microbiota?
Clinical implications
Research implications
Strengths and limitations
Conclusion
Acknowledgment
Supplementary Methods
Subjects
EF aspiration
Endometrial receptivity diagnosis
Genomic DNA isolation from EF and vaginal aspirate samples
Polymerase chain reaction and pyrosequencing
Quality control of the FASTQ files
Receiver operating characteristic
Supplementary Data
- Table S1
Bacterial communities identified in EF and VA samples.
- Table S2
Bacterial communities identified in endometrial samples at LH+2 and LH+7.
- Table S3
Bacterial communities identified in EF from IVF patients.
- Powerpoint
References
- Potential influence of the microbiome on infertility and assisted reproductive technology.Semin Reprod Med. 2014; 32: 35-42
- SnapShot: the human microbiome.Cell. 2014; 158: 690-691
- Evaluation of the bacterial vaginal flora of 20 postmenopausal women by direct (Nugent score) and molecular (polymerase chain reaction and denaturing gradient gel electrophoresis) techniques.J Infect Dis. 2002; 186: 1770-1780
- Genetic diversity of vaginal lactobacilli from women in different countries based on 16S rRNA gene sequences.J Appl Microbiol. 2002; 92: 451-459
- Temporal dynamics of the human vaginal microbiota.Sci Transl Med. 2012; 4 (132ra52)
- The human microbiome during bacterial vaginosis.Clin Microbiol Rev. 2016; 29: 223-238
- The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women.Microbiome. 2014; 2: 4
- Vaginal microbiome of reproductive-age women.Proc Natl Acad Sci U S A. 2011; 108: 4680-4687
- The vaginal microbiota of pregnant women who subsequently have spontaneous preterm labor and delivery and those with a normal delivery at term.Microbiome. 2014; 2: 18
- Influence of bacterial vaginosis on conception and miscarriage in the first trimester: cohort study.BMJ. 1999; 319: 220-223
- Abnormal bacterial colonization of the genital tract and subsequent preterm delivery and late miscarriage.BMJ. 1994; 308: 295-298
- Bacterial vaginosis, the inflammatory response and the risk of preterm birth: a role for genetic epidemiology in the prevention of preterm birth.Am J Obstet Gynecol. 2004; 190: 1509-1519
- Microbial flora of the cervix assessed at the time of embryo transfer adversely affects in vitro fertilization outcome.Fertil Steril. 1998; 70: 866-870
- Incidence of microbial growth from the tip of the embryo transfer catheter after embryo transfer in relation to clinical pregnancy rate following in-vitro fertilization and embryo transfer.Hum Reprod. 1996; 11: 1687-1689
- Bacteria in the transfer catheter tip influence the live-birth rate after in vitro fertilization.Fertil Steril. 2000; 74: 1118-1124
- Bacterial colonization of the uterine cervix and success rate in assisted reproduction: results of a prospective survey.Hum Reprod. 2002; 17: 337-340
- Examination of bacterial contamination at the time of embryo transfer, and its impact on the IVF/pregnancy outcome.J Assist Reprod Genet. 2007; 24: 395-399
- Can endometrial infection/inflammation explain implantation failure, spontaneous abortion, and preterm birth after in vitro fertilization?.Fertil Steril. 2004; 82: 799-804
- Sterility of the uterine cavity.Acta Obstet Gynecol Scand. 1995; 74: 216-219
- Colonization of the upper genital tract by vaginal bacterial species in nonpregnant women.Am J Obstet Gynecol. 2015; 212: 611.e1-611.e9
- Viral infection of the pregnant cervix predisposes to ascending bacterial infection.J Immunol. 2013; 191: 934-941
- The human microbiome: at the interface of health and disease.Nat Rev Genet. 2012; 13: 260-270
- PGE2 and PGF2 concentrations in human endometrial fluid as biomarkers for embryonic implantation.J Clin Endocrinol Metab. 2013; 98: 4123-4132
- The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure.Fertil Steril. 2013; 100: 818-824
- Improved detection of bifidobacteria with optimized 16S rRNA-gene based pyrosequencing.PLoS One. 2012; 7: e32543
- QIIME allows analysis of high-throughput community sequencing data.Nat Methods. 2010; 7: 335-336
- Search and clustering orders of magnitude faster than BLAST.Bioinformatics. 2010; 26: 2460-2461
- The ribosomal database project: improved alignments and new tools for rRNA analysis.Nucleic Acids Res. 2009; 37: D141-D145
Shannon CE. The mathematical theory of communication. University of Illinois Press. Illinis book edition, 1963.
Simpson EH. Measurement of diversity. Nature 1949;163:688-8.
- Temporal and spatial variation of the human microbiota during pregnancy.Proc Natl Acad Sci U S A. 2015; 112: 11060-11065
- Inhibition of Neisseria gonorrhoeae epithelial cell interactions by vaginal Lactobacillus species.Infect Immun. 2008; 76: 3124-3130
- The dynamics of the vaginal microbiome during infertility therapy with in vitro fertilization-embryo transfer.J Assist Reprod Genet. 2012; 29: 105-115
- The influence of bacterial vaginosis on in-vitro fertilization and embryo implantation during assisted reproduction treatment.Hum Reprod. 1999; 14: 2411-2415
- Risks associated with bacterial vaginosis in infertility patients: a systematic review and meta-analysis.Hum Reprod. 2013; 28: 1809-1815
- Prophylactic antibiotics and endocervical microbial inoculation of the endometrium at embryo transfer.Lancet. 1999; 354: 651-652
- Endometrial microbiome at the time of embryo transfer: next-generation sequencing of the 16S ribosomal subunit.J Assist Reprod Genet. 2016; 33: 129-136
- Vaginal lactobacilli inhibiting growth of Gardnerella vaginalis, Mobiluncus and other bacterial species cultured from vaginal content of women with bacterial vaginosis.Acta Pathol Microbiol Immunol Scand B. 1986; 94: 399-403
- Bacterial populations in the vaginas of healthy adolescent women.J Pediatr Adolesc Gynecol. 2009; 22: 11-18
- Embryologic outcome and secretome profile of implanted blastocysts obtained after coculture in human endometrial epithelial cells versus the sequential system.Fertil Steril. 2010; 93: 774-782.e1
Cha J, Vilella F, Dey SK, Simón C. Molecular interplay in successful implantation. Science. S. Sanders. Washington; Nov. 12, 2013; Ten critical topics in reproductive medicine: 44-8.
Article info
Publication history
Footnotes
This work was equally supported by Igenomix SL and Lifesequencing SL. I.M. holds a Torres-Quevedo grant (PTQ-13-06133) from the Spanish Ministry of Economy and Competitiveness. F.V. was partially supported by Miguel Servet Program Type I Instituto de Salud Carlos III (CP13/00038), and Fondo de Investigación Sanitaria project (PI14/00545).
Disclosure: I.M., D.V., J.J-A., R.A., and C.S. are employed by Igenomix SL. J.F.M-B., F.M.C., and D.R. are employed by Lifesequencing SL. P.A. and J.R. are employed by IVI Valencia, and A.P. by IVI Rome. F.V. reports no conflict of interest.